Digital AI is reshaping drug discovery - Now it must prove it can be... As innovation pushes the boundaries of speed and scale, a question remains: can we use transparency as a way to prove safety and build public trust?
Patients Streamlining post-trial treatment access for rare disease pa... Companies have a practical and ethical responsibility to continue treating patients when clinical trial data collection ends mid-trial.
News Controversial project aims to make artificial human genomes A landmark project funded by Wellcome aims to develop the tools needed to synthesise human genomes – and simultaneously probe the social implications.
Sales & Marketing Sponsored 12 Questions with Jackie Marchington Jackie Marchington is Head of Compliance and Ethics for IPG Health Medical Communications.
Digital How can digital technologies help pharma meet the changing n... Digital technologies are transforming the pharmaceutical industry's ability to meet the evolving needs of healthcare professionals (HCPs) and patients.
Market Access The politics of health: How elections will impact life scien... The global landscape for medical technology, biotechnology, and life sciences is on the cusp of seismic change.
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.